These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2965154)

  • 1. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.
    Porzsolt F; Messerer D; Hautmann R; Gottwald A; Sparwasser H; Stockamp K; Aulitzky W; Moormann JG; Schumacher K; Rasche H
    J Cancer Res Clin Oncol; 1988; 114(1):95-100. PubMed ID: 2965154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
    Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
    Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
    Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
    Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
    Fosså SD; Gunderson R; Moe B
    Cancer; 1990 Jun; 65(11):2451-4. PubMed ID: 2337859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advantages and problems of multicenter therapy studies exemplified by a study of the treatment of metastasizing renal cell carcinoma with recombinant interferon-alpha-2c].
    Messerer D; Porzsolt F; Hasford J; Neiss A
    Onkologie; 1987 Feb; 10(1):43-9. PubMed ID: 2954005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.
    Negrier S; Perol D; Ravaud A; Chevreau C; Bay JO; Delva R; Sevin E; Caty A; Escudier B;
    Cancer; 2007 Dec; 110(11):2468-77. PubMed ID: 17932908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.
    Atzpodien J; Kirchner H; Hänninen EL; Deckert M; Fenner M; Poliwoda H
    Eur J Cancer; 1993; 29A Suppl 5():S6-8. PubMed ID: 8260264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
    Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is interferon with or without vinblastine the "treatment of choice" in metastatic renal cell carcinoma? The Norwegian Radium Hospital's experience 1983-1986.
    Fosså SD
    Semin Surg Oncol; 1988; 4(3):178-83. PubMed ID: 3055161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial.
    Steineck G; Strander H; Carbin BE; Borgström E; Wallin L; Achtnich U; Arvidsson A; Söderlund V; Näslund I; Esposti PL
    Acta Oncol; 1990; 29(2):155-62. PubMed ID: 2185803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study.
    Pizzocaro G; Piva L; Di Fronzo G; Giongo A; Cozzoli A; Dormia E; Minervini S; Zanollo A; Fontanella U; Longo G
    J Urol; 1987 Dec; 138(6):1379-81. PubMed ID: 2824861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chemo-immuno-hormonotherapy of advanced renal cell carcinoma.
    Panetta A; Martoni A; Guaraldi M; Tamberi S; Casadio M; Lelli G; Pannuti F
    J Chemother; 1994 Oct; 6(5):349-53. PubMed ID: 7861200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma.
    Kriegmair M; Oberneder R; Hofstetter A
    Urology; 1995 May; 45(5):758-62. PubMed ID: 7747370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
    Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
    Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic renal cell carcinoma arising in a congenital solitary kidney. Treatment with interferon-containing combinations. A case report and a review of the literature.
    Merimsky O; Laufer R; Chaitchik S
    J Urol (Paris); 1989; 95(4):243-5. PubMed ID: 2529317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.